Fresenius Kabi launches biosimilar adalimumab IDACIO in Germany

Fresenius Kabi is launching its first biosimilar in Germany following the European Commission (EC) granting marketing authorization for IDACIO® for all indications of the reference medicine in the areas of rheumatology, gastroenterology and dermatology.

To read more Press Release articles, click here.